CTH120 is an investigational drug that modulates neuroplasticity, a property of the brain affected in many neurodevelopmental disorders, including attention-deficit/hyperactivity disorder (ADHD), Down...
Connecta Therapeutics, a clinical stage biotechnology company focusing on the development of new treatments for central nervous system (CNS) disorders without therapeutic options, has been granted ...
Connecta Therapeutics has closed a €1.7 million round of investment led by Inveready that will allow the company to take its first drug through to phase IIa clinical trials in patients who have frag...
Connecta Therapeutics has closed a €1.7 million round of investment led by Inveready that will allow the company to take its first drug through to phase IIa clinical trials in patients who have frag...